A multifunctional curcumin–Fe3O4@ZIF-8 nanoformulation as a T2 MRI contrast agent and pH-responsive theranostic platform for targeted ROS generation, radiosensitization, and triple-negative breast cancer treatment

Triple-negative breast cancer is one of the most aggressive and treatment-resistant malignancies. Curcumin–Fe 3 O 4 ZIF-8 NPs provide pH-responsive therapy of TNBC, improved T 2 contrast, tumor-selective curcumin release and ROS-mediated cell death.